Hayes News

Hayes News Service keeps our clients up to date with late-breaking news from clinical trials, coverage decisions, and new product approvals. We focus on emerging technologies with potentially high clinical and financial impact as soon as they are announced publicly.

Our analysts scan more than 75 peer-reviewed journals and news briefings from government agencies, medical associations, and research institutes. Results of selected studies or articles are summarized and posted with a brief commentary on whether the findings are likely to have a substantial impact.

    USPSTF Draft Guidance: Colorectal Cancer Screening

    The United States Preventive Services Task Force (USPSTF) has released a new draft recommendation statement on screening for colorectal cancer. The draft statement includes a new recommendation for screening for colorectal cancer in adults ages 45 to 49 years.

    read more

    USPSTF Draft Guidance: Colorectal Cancer Screening

    The United States Preventive Services Task Force (USPSTF) has released a new draft recommendation statement on screening for colorectal cancer. The draft statement includes a new recommendation for screening for colorectal cancer in adults ages 45 to 49 years.

    read more

    FDA Approves First Treatment for Ebola Virus

    The Food and Drug Administration (FDA) has approved Inmazeb (atoltivimab, maftivimab, and odesivimab-ebgn; Regeneron Pharmaceuticals), a mixture of three monoclonal antibodies, for treatment of Zaire ebolavirus (Ebola virus) inflection in adult and pediatric patients.

    read more

    FDA Recommends Market Withdrawal for Makena

    The Food and Drug Administration (FDA) has proposed that Makena (hydroxyprogesterone caproate injection; AMAG Pharmaceuticals) be withdrawn from the market because the required post-market study failed to verify clinical benefit, and the available evidence does not show Makena is effective for its approved use.

    read more

    FDA Approves Drug Combination for Mesothelioma

    The Food and Drug Administration (FDA) has approved Opdivo (nivolumab; Bristol-Myers Squibb) in combination with Yervoy (ipilimumab; Bristol-Myers Squibb) for the first-line treatment of adults with malignant pleural mesothelioma that cannot be removed by surgery.

    read more